COMPARATIVE ANALYSIS OF PHARMACOKINETIC (PK) STUDY DATA BETWEEN EXTENDED HALF-LIFE (EHL) AND STANDARD HALF-LIFE (SHL) FACTOR PRODUCTS: EXPERIENCE FROM GREEK ADULT HAEMOPHILIA CENTRE

被引：0
|
作者：
Christoforou, P. [1 ,2 ]
Kourampa, A. [1 ,2 ]
Varaklioti, A. [1 ,2 ]
Pirpiri, T. [1 ,2 ]
Balomenou, A. [1 ,2 ]
Katsarou, O. [1 ,2 ]
机构：
[1] Laikon Gen Hosp, Blood Unit, Athens, Greece
[2] Laikon Gen Hosp, Natl Reference Ctr Congenital Bleeding Disorders, Athens, Greece
来源：
HAEMOPHILIA | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO074
引用
收藏
页码：61 / 61
页数：1
相关论文
共 50 条
  • [21] Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients
    Rakmanotham, Arunothai
    Moonla, Chatphatai
    Sosothikul, Darintr
    HAEMOPHILIA, 2023, 29 (01) : 156 - 164
  • [22] REAL WORLD DATA ANALYSIS OF US CLAIMS DATABASE ON COAGULATION FACTOR IX EXPENDITURES IN PATIENTS WITH HEMOPHILIA B: STANDARD HALF-LIFE VS. EXTENDED HALF-LIFE PRODUCTS
    Spurden, D.
    Chhabra, A.
    Tortella, B. J.
    Fogarty, P. F.
    Rubinstein, E.
    Pleil, A.
    Alvir, J.
    VALUE IN HEALTH, 2018, 21 : S262 - S262
  • [23] Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B
    Mahlangu, Johnny N.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2018, 9 (11) : 335 - 346
  • [24] FACTOR DISPENSATION AND EXPENDITURES IN HEMOPHILIA B PATIENTS SWITCHING FROM STANDARD HALF-LIFE TO EXTENDED HALF-LIFE RECOMBINANT FACTOR IX REPLACEMENT PRODUCTS: REAL-WORLD ANALYSIS IN JAPAN
    Karumori, T.
    Chhabra, A.
    Alvir, J.
    Fogarty, P. F.
    Spurden, D.
    Tortella, B. J.
    Rubinstein, E.
    Pleil, A.
    VALUE IN HEALTH, 2018, 21 : S111 - S111
  • [25] REAL WORLD FACTOR DISPENSATION AND EXPENDITURES IN US PATIENTS WITH HEMOPHILIA B: STANDARD HALF-LIFE VS. EXTENDED HALF-LIFE FACTOR IX REPLACEMENT PRODUCTS
    Chhabra, A.
    Spurden, D.
    Tortella, B. J.
    Fogarty, P. F.
    Pleil, A.
    Rubinstein, E.
    Alvir, J.
    VALUE IN HEALTH, 2018, 21 : S111 - S111
  • [26] Cost analysis of extended half-life recombinant factor IX products in the treatment of haemophilia B in Italy : an update
    Aiello, Andrea
    Mancuso, Maria E.
    Leone, Serena
    Rossi, Letizia
    Cioni, Lorenzo
    Teruzzi, Cristina
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2022, 9 : 9 - 13
  • [27] MAJOR ORTHOPEDIC SURGERIES USING EXTENDED HALF-LIFE (EHL) COAGULATION REPLACEMENT FACTORS: THE EXPERIENCE OF A GREEK COMPREHENSIVE HAEMOPHILIA TREATMENT CENTER (CHTC)
    Kouramba, A.
    Georgopoulou, A. N.
    Zannou, A.
    Kosmas, P.
    Galopoulos, D.
    Chatzidavid, S.
    Christidi, S.
    Thivaios, G. C.
    HAEMOPHILIA, 2022, 28 : 69 - 70
  • [28] COST OF STANDARD HALF-LIFE VERSUS EXTENDED HALF-LIFE RECOMBINANT COAGULATION FACTOR VIII IN PATIENTS WITH HEMOPHILIA A IN SPAIN: RESULTS FROM A PROBABILISTIC MODEL
    Peral, C.
    Kim, H. K.
    Rubio-Rodriguez, D.
    Rubio Terres, C.
    VALUE IN HEALTH, 2019, 22 : S421 - S422
  • [29] Benefit of a multidisciplinary team approach to switching from standard to extended half-life products for prophylaxis in Haemophilia A and B patients
    Talks, Kate
    Vowles, Julie
    HAEMOPHILIA, 2018, 24 : 114 - 114
  • [30] Pharmacokinetic and safety considerations when switching from standard to extended half-life clotting factor concentrates in hemophilia
    Morfini, Massimo
    Farrugia, Albert
    EXPERT REVIEW OF HEMATOLOGY, 2019, 12 (10) : 883 - 892
12345